TWC
LCTX icon

TD Waterhouse Canada’s Lineage Cell Therapeutics LCTX Stock Holding History

TD Waterhouse Canada’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95K Hold
1,500
– – ﹤0.01% 2128
2026
Q1 		$2.36K Hold
1,500
– – ﹤0.01% 2023
2025
Q4 		$2.48K Hold
1,500
– – ﹤0.01% 1804
2025
Q3 		$2.56K Buy
+1,500
New +$1.77K ﹤0.01% 1793

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TD Waterhouse Canada's LCTX Position: Q2 2026 in Review

TD Waterhouse Canada held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 1,500 shares worth $1.95K. The position accounts for ﹤0.01% of the portfolio, ranked #2128.

TD Waterhouse Canada first reported a position in LCTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.56K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • TD Waterhouse Canada held 1,500 shares of Lineage Cell Therapeutics worth $1.95K as of Q2 2026.
  • TD Waterhouse Canada left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2128 holding.
  • TD Waterhouse Canada first reported a position in Lineage Cell Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • TD Waterhouse Canada's Lineage Cell Therapeutics position peaked at $2.56K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.